A recent study reaffirmed the safety and effectiveness of guselkumab, in managing psoriasis and psoriatic arthritis over an extended period of 208 weeks (approximately 4 years). This ...
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...
The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...
Objective: To evaluate the long-term effectiveness and tolerability of adalimumab in the treatment of psoriatic arthritis (PsA ... lymphoma or carcinoma, drug-induced lupus, or congestive heart ...
6don MSN
Indeed, it's often described as a "wonder drug." That hasn’t stopped a torrent of fat phobia and often frankly hateful cultural attitudes towards weight the drugs have helped fuel, despite having ...
The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...
Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback